Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases
March 1st, 2024
The protocol here demonstrates a fast and standardized microbiological rapid on-site evaluation (M-ROSE) workflow, including three steps: slide making, staining, and interpretation. This protocol will help physicians make rapid clinical decisions.
Our intent to introduce a real time rapid assessment method, M-ROSE, to assist physicians for formulating accurate treatment strategies for patient with primary infections. Rapid cell staining technology and a high definition microscopic imaging system are currently used to advance research in the field. The number of clinical studies on M-ROSE is relatively limited.
The biggest challenge is interpretation of M-ROSE results, which requires personnel, and well trained personnel as it is difficult to visually identify pathogens and differentiate between infection and contamination. With a better understanding of pathogens cause infections in real time, physicians can avoid an unnecessary broad spectrum antibiotics contributing to antibiotic resistance and to enhance the treatment of primary infections. M-ROSE is real time and highly efficient.
M-ROSE enables the macroscopic identification of pathogens such as aspergillus, cryptococcus, pneumocystis and candida. It holds significant guiding implications in sizing respiratory basic quality, distinguishing infectious from non-infectious disease, discriminating infection from contamination, as well as evaluating infection, civil royalty and prognose. To begin, obtain all the required materials for M-ROSE and place the complete set of Diff-Quik or DQ staining solutions in glass staining jars with sealed lids.
For roll slide preparation, extract tissue particles with a 2.5 to five milliliter disposable syringe needle. Then spread a circular area of moderate thickness from the inner to the outer one third section of the cytology slide. Submerge the slide in diff a solution for 10 to 30 seconds.
To remove excess diff a solution, put the slide in the PBS dye bath and rock it slightly up and down. Then gently shake off any remaining buffer. Immerse the slide in diff b solution for 20 to 40 seconds.
Then put the slide into the water dying tank and rock it slightly up and down. Finally, using absorbent paper, wipe off the residual liquid from the slide and proceed for microscopic examination. M-ROSE of patient bronchoscopic biopsy sample using DQ staining identified pneumocystis characterized by a clear structure, sharp contrast, and ascus.
Overview
This protocol introduces the microbiological rapid on-site evaluation (M-ROSE) workflow, which includes slide making, staining, and interpretation. It aims to assist physicians in making rapid clinical decisions regarding primary infections.
Key Study Components
Area of Science
- Microbiology
- Clinical Diagnostics
- Infectious Diseases
Background
- M-ROSE is designed for real-time assessment of primary infections.
- It utilizes rapid cell staining technology and high-definition imaging.
- Interpretation of results is a significant challenge due to the need for trained personnel.
- Understanding pathogens in real-time can help reduce unnecessary antibiotic use.
Purpose of Study
- To provide a standardized workflow for rapid clinical evaluation.
- To enhance treatment strategies for patients with infections.
- To improve the accuracy of pathogen identification.
Methods Used
- Slide making for sample preparation.
- Staining techniques for visualizing pathogens.
- High-definition microscopic imaging for result interpretation.
- Training protocols for personnel to improve interpretation accuracy.
Main Results
- M-ROSE allows for rapid assessment of infections.
- Improved understanding of pathogens aids in treatment decisions.
- Challenges in interpretation highlight the need for trained staff.
- Potential to reduce antibiotic resistance through better targeting.
Conclusions
- M-ROSE is an efficient method for real-time clinical evaluation.
- It supports physicians in making informed treatment choices.
- Further studies are needed to expand its clinical application.
Frequently Asked Questions
Executive Industry Relevance
Rapid, on-site microbiological evaluation (M-ROSE) addresses a critical bottleneck in pulmonary infectious disease management by enabling real-time pathogen identification directly from patient samples. This capability supports more precise and timely anti-infective therapy decisions, reducing empirical antibiotic misuse and enhancing portfolio-wide predictive confidence in infectious disease R&D. Integrating M-ROSE into early diagnostic workflows can de-risk therapeutic strategies and inform translational research on antimicrobial resistance.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables rapid hypothesis testing regarding infectious etiology in pulmonary samples.
- Supports biological de-risking by distinguishing infection from contamination at the point of care.
- Facilitates functional validation of diagnostic targets through direct microscopic visualization.
Screening & Assay Development
- Provides a standardized workflow for preparing and staining clinical samples for downstream analysis.
- Delivers reproducible, quantitative microscopic outputs to support assay development.
- Enables rapid screening of pathogen presence, supporting scalable diagnostic platforms.
Translational & Preclinical Research
- Aligns with translational biomarker strategies by linking real-time pathogen detection to clinical outcomes.
- Supports continuity from discovery through preclinical validation by informing infection models.
- Reduces risk of late-stage failure due to misidentified infectious agents.
Pipeline & Workflow Integration
M-ROSE fits at the interface of early diagnostic discovery and translational research, bridging sample acquisition, rapid analysis, and actionable clinical insights.
- Discovery Biology: Accelerates hypothesis testing and clarifies infection pathways in respiratory disease models.
- Screening: Standardizes sample preparation and staining for consistent, interpretable outputs.
- Analytics: Provides quantitative microscopic data to compare infection status across samples.
- Translational Research: Informs biomarker alignment and supports preclinical infection model validation.
- Enterprise Reuse: Establishes a reusable, rapid diagnostic capability for diverse infectious disease programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in pathogen identification and target validation.
- Operational Value: Delivers rapid, standardized, and scalable diagnostic workflows.
- Strategic Value: Enables more informed go/no-go decisions and reduces unnecessary antibiotic exposure.
- Portfolio Impact: Supports risk-adjusted prioritization of anti-infective and diagnostic assets.
Implementation Considerations
- Requires personnel with expertise in microscopic pathogen identification and slide interpretation.
- Needs access to rapid cell staining reagents and high-definition imaging systems.
- Demands cross-team standardization for reproducible sample processing and analysis.
- Adaptation may be needed for different respiratory sample types and infectious agents.
- Interpretation complexity and limited clinical study data may constrain immediate scalability.
